Ubiquitination-related regulator UBTD1 closely associated with Immune Escape and suppressed cells ferroptosis in Colorectal Carcinogenesis

Author:

Jin Yuzhao1,Chen Qianping1,Tang Bufu2,Mao Wei1,Wang Lu1,Lan Huiyin1,Jiang Jin3,Bai Minghua1,Zhu Ji1

Affiliation:

1. The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital)

2. Fudan University

3. The First Hospital of Jiaxing Affiliated to Jiaxing University

Abstract

Abstract Immunotherapy based on immune checkpoint inhibitors is currently a hot topic of investigation in the therapy of colorectal cancer (CRC). The most reliable predictors of immune effectiveness are, at present, microsatellite instability (MSI) and mismatch repair gene status (MMR).In contrast, other immune efficacy predictors remain desirable to facilitate individualized immunotherapy for CRC patients. Ubiquitination and its associated ubiquitin-binding enzymes and ligases regulate the tumor microenvironment and antitumor immunity to mediate tumor pathogenesis and progression. Here, we examined the molecular characteristics and immunomodulatory effects of ubiquitination-associated genes mediating the prognosis of CRC cancer. UBTD1 was identified as a significant prognostic, predictive gene for CRC, involved in regulating the immune checkpoint levels and immune cell function of CRC patients. Briefly, high expression of UBTD1 tended to enhance the presence of immune checkpoints to induce immune escape and inhibit the onset of ferroptosis. Our study demonstrated that UBTD1 was a prognostic marker for CRC in the regulation of ubiquitination and the tumor immune microenvironment and may serve as a predictor of immune efficacy and a modulator of ferroptosis.

Publisher

Research Square Platform LLC

Reference52 articles.

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2018;68:394–424.

2. From tumour heterogeneity to advances in precision treatment of colorectal cancer;Punt CJA;Nat Rev Clin Oncol,2017

3. Recent developments in the treatment of metastatic colorectal cancer;Loree JM;Ther Adv Med Oncol,2017

4. Zhu J, Liu A, Sun X, Liu L, Zhu Y, Zhang T et al. Multicenter, Randomized, Phase III Trial of Neoadjuvant Chemoradiation With Capecitabine and Irinotecan Guided by UGT1A1 Status in Patients With Locally Advanced Rectal Cancer. J Clin Oncol.:10.

5. Tumour-intrinsic resistance to immune checkpoint blockade;Kalbasi A;Nat reviews Immunol NIH Public Access,2020

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3